This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our
Privacy Policy.
Accept
Gain insight into
research trends
and
influential papers
with
Research Intelligence.
Search everything
Product tour
About us
Our data
Use cases
Pricing
Sign in
Sign up
Home
Research Intelligence
Pro
Expert Finder
Pro
Scinapse Trends
Paper Search
Journal Search
Collections
Favorites
History
Notes
Keyword Alerts
Submit Feedback
Settings
doi.org/10.1182/blood.2020006315
Other
Emicizumab for the treatment of acquired hemophilia A
Paul Knoebl
26
,
J. Thaler
39
,
...,
Wolfgang R. Sperr
89
View all 6 authors
Blood
21.00
Volume: 137, Issue: 3, Pages: 410 - 419
Published
: Aug 7, 2020
120
Citations
Source
Cite
Save
Basic Info
Analytics
References
Citations
Abstract
No abstract.
Paper Fields
Coagulation
Internal medicine
Immunology
Partial thromboplastin time
Research methodology
Medicine
Titer
Breakthrough bleeding
Rituximab
Population
Gastroenterology
Surgery
Environmental health
Interquartile range
Antibody
Family planning
Paper Details
Title
Emicizumab for the treatment of acquired hemophilia A
DOI
doi.org/10.1182/blood.2020006315
Published Date
Aug 7, 2020
Journal
Blood
Volume
137
Issue
3
Pages
410 - 419
Notes
To use the Note feature, you need to be logged in. Please
sign in.
History
View all history
Bayesian Degradation Analysis With Inverse Gaussian Process Models Under Time-Varying Degradation Rates
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.
Skip
Next